Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale

References

• DeFronzoRAEldorRAbdul-GhaniMPathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetesDiabetes Care201336Suppl 2 S127 S13823882037
   PubMed Web of Science ®Google Scholar
• DefronzoRABanting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitusDiabetes2009584 773 79519336687
   PubMed Web of Science ®Google Scholar
• InzucchiSEBergenstalRMBuseJBManagement of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care2015381 140 14925538310
   PubMed Web of Science ®Google Scholar
• Stark CasagrandeSFradkinJESaydahSHRustKFCowieCCThe prevalence of meeting A1C, blood bressure, and LDL goals among people with diabetes, 1988–2010Diabetes Care2013368 2271 227923418368
   PubMed Web of Science ®Google Scholar
• ZinmanBInitial combination therapy for type 2 diabetes mellitus: is it ready for prime time?Am J Med20111241 Suppl S19 S3421194577
   PubMed Web of Science ®Google Scholar
• Abdul-GhaniMWhere does combination therapy with an SGLT2 inhibitor plus a DPP-4 inhibitor fit in the management of type 2 diabetes?Diabetes Care2015383 373 37525715413
   PubMed Web of Science ®Google Scholar
• American Diabetes Association7. Approaches to glycemic treatmentDiabetes Care201639Suppl 1 S52 S5926696682
   PubMed Web of Science ®Google Scholar
• GarberAJAbrahamsonMJBarzilayJIConsensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – 2016 executive summaryEndocr Pract2016221 84 11326731084
   PubMed Web of Science ®Google Scholar
• AhrénBSimonssonELarssonHInhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetesDiabetes Care2002255 869 87511978683
   PubMed Web of Science ®Google Scholar
• DeaconCFDipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative reviewDiabetes Obes Metab2011131 7 1821114598
   PubMed Web of Science ®Google Scholar
• BalasBBaigMRWatsonCThe dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patientsJ Clin Endocrinol Metab2007924 1249 125517244786
   PubMed Web of Science ®Google Scholar
• ScheenAJA review of gliptins in 2011Expert Opin Pharmacother2012131 81 9922149369
   PubMed Web of Science ®Google Scholar
• ScheenAJA review of gliptins for 2014Expert Opin Pharmacother2015161 43 6225381751
   PubMed Web of Science ®Google Scholar
• BaettaRCorsiniAPharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differencesDrugs20117111 1441 146721812507
   PubMed Web of Science ®Google Scholar
• ScheenAJPharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetesClin Pharmacokinet2015541 1 2125331711
   PubMed Web of Science ®Google Scholar
• Merck & Co IncPrescribing Information (08/2015): JANUVIA^® (sitagliptin) Tablets Available from: http://www.accessdata.fda.gov/drug-satfda_docs/label/2015/021995s034lbl.pdfAccessed June 20, 2016
   Google Scholar
• Bristol-Myers Squibb CompanyPrescribing Information (04/2016): ONGLYZA (saxagliptin) Tablets, for Oral Use Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022350s014lbl.pdfAccessed June 20, 2016
   Google Scholar
• Boehringer Ingelheim Pharmaceuticals, IncPrescribing Information (08/2015): Tradjenta® (linagliptin) Tablets Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/201280s012lbl.pdfAccessed June 20, 2016
   Google Scholar
• Takeda Pharmaceuticals USA, IncPrescribing Information (05/2016): NESINA (alogliptin) Tablets Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022271s009lbl.pdfAccessed June 20, 2016
   Google Scholar
• AschnerPKipnesMSLuncefordJKEffect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetesDiabetes Care20062912 2632 263717130196
   PubMed Web of Science ®Google Scholar
• RosenstockJAguilar-SalinasCKleinEEffect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetesCurr Med Res Opin20092510 2401 241119650754
   PubMed Web of Science ®Google Scholar
• Del PratoSBarnettAHHuismanHNeubacherDWoerleHJDugiKAEffect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trialDiabetes Obes Metab2011133 258 26721205122
   PubMed Web of Science ®Google Scholar
• DeFronzoRAFleckPRWilsonCAMekkiQAlogliptin Study 010 GroupEfficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled studyDiabetes Care20083112 2315 231718809631
   PubMed Web of Science ®Google Scholar
• CraddyPPalinHJJohnsonKIComparative effectiveness of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparisonDiabetes Ther201451 1 4124664619
   PubMed Web of Science ®Google Scholar
• ZhangXZhaoQEffects of dipeptidyl peptidase-4 inhibitors on blood pressure in patients with type 2 diabetes: a systematic review and meta-analysisJ Hypertens2016342 167 17526682782
   PubMed Web of Science ®Google Scholar
• ScheenAJSafety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetesExpert Opin Drug Saf2015144 505 52425630605
   PubMed Web of Science ®Google Scholar
• KaragiannisTBouraPTsapasASafety of dipeptidyl peptidase 4 inhibitors: a perspective reviewTher Adv Drug Saf201453 138 14625083269
   PubMedGoogle Scholar
• SciricaBMBhattDLBraunwaldESaxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitusN Engl J Med201336914 1317 132623992601
   PubMed Web of Science ®Google Scholar
• ZannadFCannonCPCushmanWCHeart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trialLancet20153859982 2067 207625765696
   PubMed Web of Science ®Google Scholar
• GreenJBBethelMAArmstrongPWEffect of sitagliptin on cardiovascular outcomes in type 2 diabetesN Engl J Med20153733 232 24226052984
   PubMed Web of Science ®Google Scholar
• TohSHamppCReichmanMERisk for hospitalized heart failure among new users of saxagliptin, sitagliptin, and other antihyperglycemic drugs: a retrospective cohort studyAnn Intern Med201616411 705 71427110660
   PubMed Web of Science ®Google Scholar
• LiLLiSDengKDipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studiesBMJ2016352 i61026888822
   PubMed Web of Science ®Google Scholar
• DeFronzoRADavidsonJADel PratoSThe role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemiaDiabetes Obes Metab2012141 5 1421955459
   PubMed Web of Science ®Google Scholar
• ZhangLFengYListJKasichayanulaSPfisterMDapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weightDiabetes Obes Metab2010126 510 51620518806
   PubMed Web of Science ®Google Scholar
• NauckMAUpdate on developments with SGLT2 inhibitors in the management of type 2 diabetesDrug Des Devel Ther20148 1335 1380
   PubMed Web of Science ®Google Scholar
• WashburnWNPoucherSMDifferentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitusExpert Opin Investig Drugs2013224 463 486
   PubMed Web of Science ®Google Scholar
• ScheenAJEvaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerationsExpert Opin Drug Metab Toxicol2014105 647 66324387329
   PubMed Web of Science ®Google Scholar
• LamosEMYounkLMDavisSNCanagliflozin, an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitusExpert Opin Drug Metab Toxicol201396 763 77523590413
   PubMed Web of Science ®Google Scholar
• KasichayanulaSLiuXLacretaFGriffenSCBoultonDWClinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2Clin Pharmacokinet2014531 17 2724105299
   PubMed Web of Science ®Google Scholar
• ScheenAJPharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitorClin Pharmacokinet2014533 213 22524430725
   PubMed Web of Science ®Google Scholar
• Janssen Pharmaceuticals IncPrescribing Information (08/2016): INVOKANA (canagliflozin) Tablets, for Oral Use Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204042s022lbl.pdfAccessed December 20, 2016
   Google Scholar
• AstraZeneca Pharmaceuticals LPPrescribing Information (08/2016): FARXIGA® (dapagliflozin) Tablets, for Oral Use Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202293s010lbl.pdfAccessed December 20, 2016
   Google Scholar
• Boehringer Ingelheim Pharmaceuticals, IncPrescribing Information (12/2016): JARDIANCE^® (empagliflozin) Tablets, for Oral Use Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204629s008lbl.pdfAccessed December 20, 2016
   Google Scholar
• GremplerRThomasLEckhardtMEmpagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitorsDiabetes Obes Metab2012141 83 9021985634
   PubMed Web of Science ®Google Scholar
• YangXPLaiDZhongXYShenHPHuangYLEfficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysisEur J Clin Pharmacol20147010 1149 115825124541
   PubMed Web of Science ®Google Scholar
• ZhangMZhangLWuBSongHAnZLiSDapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trialsDiabetes Metab Res Rev2014303 204 22124115369
   PubMed Web of Science ®Google Scholar
• LiakosAKaragiannisTAthanasiadouEEfficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysisDiabetes Obes Metab20141610 984 99324766495
   PubMed Web of Science ®Google Scholar
• FerranniniERamosSJSalsaliATangWListJFDapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trialDiabetes Care20103310 2217 222420566676
   PubMed Web of Science ®Google Scholar
• StenlöfKCefaluWTKimKAEfficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exerciseDiabetes Obes Metab2013154 372 38223279307
   PubMed Web of Science ®Google Scholar
• RodenMWengJEilbrachtJEmpagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trialLancet Diabetes Endocrinol201313 208 21924622369
   PubMed Web of Science ®Google Scholar
• GeerlingsSFonsecaVCastro-DiazDListJParikhSGenital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuriaDiabetes Res Clin Pract20141033 373 38124529566
   PubMed Web of Science ®Google Scholar
• JohnssonKMPtaszynskaASchmitzBSuggJParikhSJListJFVulvovaginitis and balanitis in patients with diabetes treated with dapagliflozinJ Diabetes Complications2013275 479 48423806570
   PubMed Web of Science ®Google Scholar
• NyirjesyPSobelJDFungAGenital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studiesCurr Med Res Opin2014306 1109 111924517339
   PubMed Web of Science ®Google Scholar
• DaileyGEmpagliflozin for the treatment of type 2 diabetes mellitus: an overview of safety and efficacy based on Phase 3 trialsJ Diabetes201574 448 46125676662
   PubMed Web of Science ®Google Scholar
• JohnssonKMPtaszynskaASchmitzBSuggJParikhSJListJFUrinary tract infections in patients with diabetes treated with dapagliflozinJ Diabetes Complications2013275 473 47823849632
   PubMed Web of Science ®Google Scholar
• NicolleLECapuanoGFungAUsiskinKUrinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitorPostgrad Med20141261 7 17
   PubMed Web of Science ®Google Scholar
• FoodUSAdministrationDrugDrug safety communication (December 4, 2015). FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections Available from: http://www.fda.gov/Drugs/DrugSafety/ucm475463.htmAccessed February 03, 2016
   Google Scholar
• PetersALBuschurEOBuseJBCohanPDinerJCHirschIBEuglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibitionDiabetes Care2015389 1687 169326078479
   PubMed Web of Science ®Google Scholar
• RoachPSkierczynskiPEuglycemic diabetic ketoacidosis in a patient with type 2 diabetes after treatment with empagliflozinDiabetes Care2016391 e326519331
   PubMed Web of Science ®Google Scholar
• HineJPatersonHAbrolERussell-JonesDHerringRSGLT inhibition and euglycaemic diabetic ketoacidosisLancet Diabetes Endocrinol201537 503 504
   PubMed Web of Science ®Google Scholar
• HaratiHSharmaVMotazediASodium-glucose cotransporter 2 inhibitor-associated diabetic ketoacidosis: report of two cases with hyperglycemic ketoacidosis in type 1 diabetesJ Diabetes201681 16526211700
   PubMed Web of Science ®Google Scholar
• GelayeAHaidarAKassabCKazmiSSinhaPSevere ketoacidosis associated with canagliflozin (Invokana): a safety concernCase Rep Crit Care20162016 165618227088018
   PubMedGoogle Scholar
• EronduNDesaiMWaysKMeiningerGDiabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical programDiabetes Care2015389 1680 168626203064
   PubMed Web of Science ®Google Scholar
• RosenstockJFerranniniEEuglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitorsDiabetes Care2015389 1638 164226294774
   PubMed Web of Science ®Google Scholar
• KasichayanulaSLiuXShyuWCLack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjectsDiabetes Obes Metab2011131 47 54
   PubMed Web of Science ®Google Scholar
• BrandTMachaSMattheusMPinnettiSWoerleHJPharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteersAdv Ther20122910 889 89923054692
   PubMed Web of Science ®Google Scholar
• FriedrichCMetzmannKRosePMattheusMPinnettiSWoerleHJA randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteersClin Ther2013351 A33 A4223328275
   PubMed Web of Science ®Google Scholar
• JabbourSAHardyESuggJParikhSStudy 10 GroupDapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled studyDiabetes Care2014373 740 75024144654
   PubMed Web of Science ®Google Scholar
• RosenstockJHansenLZeePDual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metforminDiabetes Care2015383 376 38325352655
   PubMed Web of Science ®Google Scholar
• MathieuCRanettiAELiDRandomized, double-blind, phase 3 trial of triple therapy with dapagliflozin add-on to saxagliptin plus metformin in type 2 diabetesDiabetes Care20153811 2009 201726246458
   PubMed Web of Science ®Google Scholar
• MatthaeiSCatrinoiuDCelinskiARandomized, double-blind trial of triple therapy with saxagliptin add-on to dapagliflozin plus metformin in patients with type 2 diabetesDiabetes Care20153811 2018 202426324329
   PubMed Web of Science ®Google Scholar
• LewinADeFronzoRAPatelSInitial combination of empagliflozin and linagliptin in subjects with type 2 diabetesDiabetes Care2015383 394 40225633662
   PubMed Web of Science ®Google Scholar
• DeFronzoRALewinAPatelSCombination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metforminDiabetes Care2015383 384 39325583754
   PubMed Web of Science ®Google Scholar
• SøftelandEMeierJJVangenBToorawaRMaldonado-LutomirskyMBroedlUCEmpagliflozin as add-on therapy in patients with type 2 diabetes inadequately controlled with linagliptin and metformin: a 24-week randomized, double-blind, parallel-group trialDiabetes Care2017402 201 20927913576
   PubMed Web of Science ®Google Scholar
• TinahonesFJGallwitzBNordabyMLinagliptin as add-on to empagliflozin and metformin in patients with type 2 diabetes: two 24-week randomized, double-blind, double-dummy, parallel-group trialsDiabetes Obes Metab2017192 266 27427762093
   PubMed Web of Science ®Google Scholar
• NeumillerJJEfficacy and safety of saxagliptin as add-on therapy in type 2 diabetesClin Diabetes2014324 170 17725646943
   PubMedGoogle Scholar
• EngelSSSeckTLGolmGTMeehanAGKaufmanKDGoldsteinBJAssessment of AACE/ACE recommendations for initial dual antihyperglycemic therapy using the fixed-dose combination of sitagliptin and metformin versus metforminEndocr Pract2013195 751 75723757615
   PubMed Web of Science ®Google Scholar
• KhuntiKWoldenMLThorstedBLAndersenMDaviesMJClinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 peopleDiabetes Care20133611 3411 341723877982
   PubMed Web of Science ®Google Scholar
• FuAZQiuYDaviesMJRadicanLEngelSSTreatment intensification in patients with type 2 diabetes who failed metformin monotherapyDiabetes Obes Metab2011138 765 76921457427
   PubMed Web of Science ®Google Scholar
• PaulSKKleinKThorstedBLWoldenMLKhuntiKDelay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetesCardiovasc Diabetol201514 10026249018
   PubMed Web of Science ®Google Scholar
• StrainWDCosXHirstMTime to do more: addressing clinical inertia in the management of type 2 diabetes mellitusDiabetes Res Clin Pract20141053 302 31224956964
   PubMed Web of Science ®Google Scholar
• NauDPRecommendations for improving adherence to type 2 diabetes mellitus therapy–focus on optimizing oral and non-insulin therapiesAm J Manag Care2012183 Suppl S49 S5422558942
   PubMedGoogle Scholar
• HauberABMohamedAFJohnsonFRFalveyHTreatment preferences and medication adherence of people with type 2 diabetes using oral glucose-lowering agentsDiabet Med2009264 416 42419388973
   PubMed Web of Science ®Google Scholar
• BarendseSSinghHFrierBMSpeightJThe impact of hypoglycaemia on quality of life and related patient-reported outcomes in type 2 diabetes: a narrative reviewDiabet Med2012293 293 30221838763
   PubMed Web of Science ®Google Scholar
• MerovciASolis-HerreraCDanieleGDapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose productionJ Clin Invest20141242 509 51424463448
   PubMed Web of Science ®Google Scholar
• FerranniniEMuscelliEFrascerraSMetabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patientsJ Clin Invest20141242 499 50824463454
   PubMed Web of Science ®Google Scholar
• SchernthanerGSchernthaner-ReiterMHHow attractive is the combination of a sodium glucose co-transporter 2 inhibitor with a dipeptidyl peptidase 4 inhibitor in the treatment of type 2 diabetes?Diabetes Obes Metab2015177 613 61526018554
   PubMed Web of Science ®Google Scholar
• SchernthanerGMogensenCESchernthanerGHThe effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal systemDiab Vasc Dis Res2014115 306 32325116004
   PubMed Web of Science ®Google Scholar
• ZinmanBWannerCLachinJMEmpagliflozin, cardiovascular outcomes, and mortality in type 2 diabetesN Engl J Med201537322 2117 212826378978
   PubMed Web of Science ®Google Scholar